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Abstract 
Background: Bariatric surgery is an effective treatment for morbid obesity. Obesity and type 
2 diabetes are associated with chronic inflammation. There is lack of data examining the 
effects of sleeve gastrectomy (SG) on inflammatory biomarkers. 
Objectives: Our aim was to study the effects of SG on specific cytokines associated with 
obesity including interleukin-6 (IL-6), interleukin-10 (IL-10), leptin, adiponectin and C-
reactive protein (CRP) preoperatively, 1 and 6 months after surgery.  
Setting: University Hospital, United Kingdom.  
Methods: A non-randomized prospective study comprising of 22 participants with impaired 
glucose homeostasis and type 2 diabetes undergoing SG (body mass index [BMI] 50.1kg/m2, 
Glycated hemoglobin [HbA1c] 53 mmol/mol). Serial measurements of IL-6, IL-10, leptin, 
adiponectin, and CRP were performed during oral glucose tolerance testing pre-operatively, 1 
and 6 months postoperatively.  
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Results: We observed significant improvements at 1 and 6 months in leptin (p=<0.001) and 
CRP (p=0.003) following SG. We also observed a significant reduction in IL-6 at 6 months 
(p=0.001). No statistically significant differences were observed for adiponectin and IL-10.  
Conclusion: This study is the first to examine the detailed changes in the inflammatory 
cytokines after SG. Our study shows significant improvements in the inflammatory 
biomarkers following SG in subjects with impaired glucose homeostasis and type 2 diabetes. 
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Introduction 
Systemic inflammation is closely associated with obesity and type 2 diabetes mellitus 
(T2DM). Prospective studies have shown that chronic low grade systemic inflammation 
predicts the future risk of impaired glucose tolerance (IGT), T2DM (1) and cardiovascular 
disease (CVD) (2). Certain subgroups of the population that are at a high risk of developing 
T2DM have elevated inflammatory markers. These include overweight adults and children, 
women with polycystic ovary syndrome, certain ethnic origins (e.g. Pima Indians) and 
participants with a family history of T2DM (3). Interestingly, these groups often also share the 
common feature of obesity. The Finnish and American Diabetes Prevention studies both 
showed a 58% reduction in progression from IGT to T2DM, by diet and exercise (4, 5). In 
addition, several of the studies looking at CVD risk reduction with statins (WOSCOPS) and 
angiotensin-1 converting enzyme inhibitors (HOPE, CAPP) showed a 25-30% reduction in 
the development of T2DM (6-8), presumably through an underlying anti-inflammatory 
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mechanism. These previously described results reinforce the close relationship between 
obesity, inflammation and T2DM. 
Adipokines are cytokines secreted by adipose tissue and can modulate immune response, 
insulin sensitivity and energy balance. Cytokines associated with obesity include interleukin-
6 (IL-6), interleukin-10 (IL-10), adiponectin, leptin and C-reactive protein (CRP) (9-11). 
Changes in plasma levels of pro-inflammatory and anti-inflammatory cytokines and 
adipokines are related to increased adipose tissue mass (1, 2).  
Bariatric surgery is effective in the treatment of obesity and T2DM and in reducing CVD risk 
factors (12). This is likely to occur through a reduction in adipose tissue mass and subsequent 
improvements in the inflammatory milieu (13, 14). Previous work has demonstrated 
malabsorptive surgery such as Laparoscopic Roux-en-Y Gastric Bypass (RYGB) is 
associated with significant reductions in serum levels of leptin and non-significant changes in 
soluble TNF-α receptor-1 and adiponectin levels 6 months following surgery (15). CRP has 
also been observed to be significantly lower at 6 months compared to preoperative values. A 
significant reduction in CRP, IL-6 and an increase in adiponectin have also been observed 6 
months after gastric bypass in another study (16) and is supported by the results of a recent 
meta-analysis (17). Over recent years an increasing number of SG operations have been 
performed relative to RYGB, Bilio-pancreatic Diversion (BPD) and laparoscopic adjustable 
Gastric Banding (LAGB) and furthermore SG is now recognized as a stand-alone bariatric 
procedure with a superior safety profile (18, 19). Prospective studies describe a reduction in 
CRP at 4 weeks in 11 patients following a SG (20) and in 37 participants at 9 months (21). An 
improvement in CRP has also been observed in a retrospective hospital database study of 61 
patients (22). However, there is limited information within the available literature with regard 
to the effects of SG on other cytokines and adipokines.  
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Our aim was to specifically examine the temporal changes in IL-6, IL-10, leptin, adiponectin 
and CRP preoperatively, 1 and 6 months after SG in a sample of subjects with impaired 
glucose tolerance or T2DM.  
 
 
Participants and methods 
 
Study participants 
Approval for the study was obtained from the Local Research Ethics Committee (South 
Wales; LREC reference 06/WMW02/7) and the Joint Scientific Research Committee at 
Swansea University and ABM University Health Board. Participants were identified and 
recruited from patients undergoing a planned bariatric surgical procedure at Welsh Institute 
of Metabolic and Obesity Surgery (WIMOS) at Morriston Hospital, ABM University Health 
Board, Swansea, Wales, UK. Entry criteria at the outset of the study included:- both sexes, 
age 20-40 years, BMI >40kg/m2 and physically fit for surgery. Participants with any acute 
concurrent illness were excluded. Participants with previously diagnosed T2DM treated with 
diet, oral agents, GLP-1 analogues or insulin were included. All participants underwent an 
oral glucose tolerance test (OGTT) prior to recruitment. Participants with impaired glucose 
regulation were those with either impaired fasting glycaemia (5.6-6.9 mmol/L) or impaired 
glucose tolerance (2-hour glucose 7.8-11.0 mmol/L) (23).  
 
Study design 
Participants with a planned SG were recruited prospectively and consecutively from the 
bariatric surgical clinic. SG is a standard sleeve i.e. sleeve fashioned around a 32F bougie 
taken from 5cm proximal to the pylorus and up to the left crus. All participants were recruited 
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pre-operatively (within 1 month of surgery) and followed up postoperatively at 1 and 6 
months. All participants with the help of the research nurse completed a baseline 
questionnaire and all clinical measurements were documented during the visits. All blood 
samples were collected after stopping any prescribed insulin or oral hypoglycaemic agent for 
24 hours prior to an OGTT performed with 75g of glucose (122mLs of Polycal 61.9g/100mL 
of glucose, Nutricia Clinical Care, Trowbridge, UK). 
 
Baseline clinical and biochemical information 
At the time of screening the following clinical information was ascertained: age, gender, past 
medical history, treatment and duration of diabetes. Baseline clinical measurements consisted 
of weight, height, BMI, waist circumference, systolic and diastolic blood pressure. Baseline 
biochemical measurements (total cholesterol, Low density lipoprotein-cholesterol [LDL-C], 
High density lipoprotein-cholesterol [HDL-C] and triglycerides) were analyzed within the 
local hospital accredited laboratory. Glucose and lipids (Roche Modular P800 Analyzer) and 
insulin and C-peptide (Roche E170 Modular Analyzer) were also measured locally. All blood 
samples were collected on ice, centrifuged and separated within one hour of collection and 
subsequently stored at -80oC until analysis. Fasting EDTA samples were collected for the 
measurement of cytokines during the OGTT at baseline, 1 and 6 months. 
 
Measurement of total cytokines 
Fasting plasma levels of IL-6, IL-10 and leptin were measured with high sensitivity ELISA 
kits (R&D Systems). Intra-assay and inter-assay variability coefficients were as follows: IL-6 
≤4.2% and ≤6.4%; IL-10, ≤5.0% and ≤7.5%; leptin, ≤3.3% and ≤5.4%.  
Fasting plasma levels of total adiponectin and CRP were measured with high sensitivity 
ELISA kits (Immundiagnostik AG). Intra-assay and inter-assay variability coefficients were 
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as follows: adiponectin, ≤3.4% and ≤6.3%; CRP, ≤6.0% and ≤13.8%. All samples were 
assayed in duplicate. 
 
Statistical methods 
Statistical analysis was performed using SPSS (version 10.1, SPSS Inc., Chicago). Results for 
continuous variables are presented as mean and standard deviation and in graphical 
representation as mean and standard error. Continuous variables that did not have a normal 
distribution (triglyceride, adiponectin, CRP and IL-6) underwent log transformation to 
normalize the data for analysis and are described with the geometric mean and approximate 
standard deviation. For continuous variables, the mean temporal changes were compared 
between baseline and 1 or 6 months using a paired t-test. Categorical data were analysed 
using a Chi-squared test. Paired t-tests were used to compare mean differences in cytokines 
between baseline, 1 and 6 months for IL-10, leptin, adiponectin, CRP and IL-6 (with log 
transformation where appropriate). In all cases a p<0.05 was considered statistically 
significant.  
 
 
Results 
 
Subject characteristics 
A total of 22 participants who underwent a SG (mean age 48±7 years) with impaired glucose 
homeostasis or T2DM (median duration of 42 month [interquartile range 21-66 months]) 
completed the study. Table 1 shows the temporal changes between baseline, 1 and 6 months 
within the group. As shown in Table 1, significant reductions were observed in weight at 1 
month with a mean reduction in BMI of 10.5kg/m2 (weight change of 31.1kg) at 6 months. 
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We also observed a significant reduction in the systolic blood pressure at 1 month but no 
significant changes in total cholesterol, LDL-C or triglyceride concentrations. Significant 
changes were observed in fasting glucose, 2-hour glucose and HbA1c. 
 
Temporal changes in inflammatory cytokines following sleeve gastrectomy 
The temporal changes in fasting inflammatory cytokines between baseline, 1 and 6 months 
are shown in Figure 1. Plasma leptin decreased by 34.4% and 43.1% respectively at 1 and 6 
months postoperatively. Compared to baseline, significant reductions of 67.5% and 44.8% 
were observed for CRP respectively. At 6 months there was a significant reduction (31.6%) 
in plasma IL-6. There was a non-significant increase of adiponectin at 6 months (p=0.15). No 
significant changes were observed in IL-10.  
 
Discussion 
Bariatric surgery in addition to weight loss effectively reduces morbidity and mortality in 
severely obese individuals with favorable effects on T2DM, hypertriglyceridaemia and 
hypertension. These effects are likely to be related to an improvement in the inflammatory 
profile caused by the rapid and significant reductions in fat mass following surgery (16). SG 
has gained recent popularity as an independent bariatric procedure (18, 19). We observed 
significant improvements in leptin and CRP at 1 month postoperatively following SG and this 
was maintained at 6 months. We also observed a reduction in IL-6 at 1 month which was 
statistically significant at 6 months. No differences were observed for adiponectin and IL-10 
following SG. Previous studies have only described changes in CRP as early as 4 weeks 
following a SG (20-22).  
We also examined the correlations between the change in BMI with the inflammatory 
biomarkers. At 1 month, there was a significant correlation between greater weight loss and 
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increased plasma IL-10 (r=0.50, p=0.008) and an inverse association between increased 
adiponectin and IL-6 (r=-0.50, p=0.04), such that an increase in adiponectin was associated 
with reduction in IL-6. These changes would be consistent with a reduction in adipose tissue 
mass being responsible for increased levels of the anti-inflammatory adipokine adiponectin 
and a reduction in the proinflammatory cytokine IL-6. This is in line with previous studies 
which have demonstrated that adipose tissue is a major source of IL-6 with as much as 30% 
of circulating IL-6 being derived from adipose tissue (24). Circulating levels of IL-6 are 
raised in insulin resistant states such as obesity (25), IGT (26) and T2DM (27-29) and previous 
prospective studies have shown plasma IL-6 to correlate with BMI, percentage fat mass and 
fasting insulin levels. Weight reduction by diet and exercise has also been shown to reduce 
plasma IL-6 levels (30).  
This study is the first to examine the temporal relationship of these inflammatory biomarkers 
at 1 and 6 months following SG. This current study contributes to the available literature 
supporting the role of SG for the treatment of T2DM, and pro-inflammatory conditions 
associated with morbid obesity. One limitation of the study was that the sample group was 
heterogeneous comprising of subjects with impaired glucose tolerance and type 2 diabetes. 
Furthermore, the duration of diabetes was variable within the study group (median 42 months 
[interquartile range 21-66 months]) and that this might have an effect on the levels of 
inflammatory markers pre-operatively. Furthermore, the duration of diabetes was obtained 
from primary care medical records and this is therefore an estimate as diabetes may be 
present for sometime before the diagnosis is made (31).  
Further prospective studies are required to examine the effects of SG in relation to 
biomarkers of inflammation and oxidative stress in relation to inflammatory medicated 
complications of obesity. 
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Table 1: Baseline and end of study clinical and biochemical measurements within the 
SG group 
 
 
Measurement Baseline 1 month aP  6 months bP  
Weight (kg) 146.6 (29.6) 129.4 (26.9) <0.001 115.5 (24.4)  <0.001 
BMI (kg/m2) 50.1 (6.6) 44.0 (6.6) <0.001 39.6 (6.2) <0.001 
Waist (cm) 138 (18) 128 (17) <0.001 118 (18) <0.001 
Systolic BP (mmHg) 131 (18) 123 (14) 0.04 128 (20) 0.12 
Diastolic BP (mmHg) 76 (11) 74 (9) 0.63 73 (14) 0.13 
Cholesterol (mmol/L) 4.3 (1.0) 4.4 (1.1) 0.58 4.7 (1.2) 0.09 
LDL-C (mmol/L) 2.4 (0.8) 2.7 (1.0) 0.16 2.8 (0.9) 0.05 
HDL-C (mmol/L) 1.2 (0.3) 1.1 (0.3) 0.02 1.3 (0.3) 0.10 
Triglyceride (mmol/L)c 1.4 (0.4) 1.4 (0.2) 0.92 1.1 (0.2) 0.15 
HbA1c (%) 
HbA1c (mmol/mol) 
7.0 (1.7) 
53 (18.6) 
6.1 (0.8) 
43 (8.7) 
0.005 
0.005 
5.7 (0.8)  
39 (8.7) 
0.002 
   0.002 
Fasting glucose (mmol/L) 7.6 (3.6) 5.4 (0.9) 0.02 5.0 (1.0) 0.08 
2-hour glucose (mmol/L) 11.6 (5.9) 7.8 (3.4) 0.002 5.4 (2.2)  <0.001 
Mean and standard deviation shown for continuous variables 
aP-value comparing baseline with 1 months.  
 bP-value comparing baseline with 6 months. 
clog transformed for analysis. Geometric mean and approximate standard deviation shown for 
log- transformed data. 
In the group there were 15 females and 7 males. 
 
 
BMI= Body mass index, LDL-C= Low density lipoprotein-Cholesterol, HDL-C= High 
density lipoprotein-Cholesterol, HbA1c= Glycated hemoglobin 
 
 
 
 
11 
 
Figure legends 
 
 
Figure 1: Temporal changes in inflammatory biomarkers following sleeve gastrectomy 
 
Mean and standard error is shown.  
*P<0.05: Significant changes relative to baseline. 
Figure 1a: Interleukin-10.  
Figure 1b: Leptin 
Figure 1c: Adiponectin 
Figure 1d: C-reactive protein  
Figure 1e: Interleukin-6 
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